RT Journal Article
SR Electronic
T1 THE TIME TO OFFER TREATMENTS FOR COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.27.20115238
DO 10.1101/2020.05.27.20115238
A1 Ngo, Binh T.
A1 Marik, Paul
A1 Kory, Pierre
A1 Shapiro, Leland
A1 Thomadsen, Raphael
A1 Iglesias, Jose
A1 Ditmore, Stephen
A1 Rendell, Marc
A1 Varon, Joseph
A1 Dubé, Michael
A1 Nanda, Neha
A1 In, Gino
A1 Arkfeld, Daniel
A1 Chaudhary, Preet
A1 Campese, Vito M.
A1 Hanna, Diana L.
A1 Sawcer, David E.
A1 Ehresmann, Glenn
A1 Peng, David
A1 Smogorewski, Miroslaw
A1 Armstrong, April
A1 Dasgupta, Rajkumar
A1 Sattler, Fred
A1 Brennan-Rieder, Denise
A1 Mussini, Cristina
A1 Mitja, Oriol
A1 Soriano, Vicente
A1 Peschanski, Nicolas
A1 Hayem, Gilles
A1 Confalonieri, Marco
A1 Piccirillo, Maria Carmela
A1 Lobo-Ferreira, Antonio
A1 Rivero, Iraldo Bello
A1 Vinjevoll, Eivind H.
A1 Griffin, Daniel
A1 Hung, Ivan FN
YR 2021
UL http://medrxiv.org/content/early/2021/01/23/2020.05.27.20115238.abstract
AB BACKGROUND As of January 1, 2021, there have been 81,947,503 confirmed cases of COVID-19, resulting in 1,808,041 deaths worldwide. Several vaccines are now available for emergency use, but it will take many months to immunize the world’s population. There is a pressing need for outpatient treatment now. We reviewed the possible optionsMETHODS We reviewed up-to-date information from several sources to identify potential treatments to be utilized now for COVID-19. We searched for all ongoing, completed and published trial results with subject numbers of 100 or more, and used a targeted search to find announcements of unpublished trial results.RESULTS As of December 27, 2020, we identified 750 trials currently in recruitment phase. Of these, 122 were directed at prevention in healthy individuals, 100 were classified as treatment of outpatients with documented infection, and 390 were for treatment of hospitalized inpatients. There were 9 trials focusing on the post discharge Tail phase. Among the trials, there were 60 vaccine trials, 120 trials of hydroxychloroquine, 33 trials of alternative therapy, 12 trials of colchicine, 38 trials of anticoagulants, 22 trials of the RNA polymerase inhibitor favipiravir (FVP), 19 trials of interferons, 18 trials of glucocorticoid, and 58 trials of plasma based products. Closure of enrollment was projected by the end of the year for 153 trials. We found 83 publications reporting findings in human studies on 14 classes of agents, and on 7 vaccines. There were 45 randomized or active controlled studies, the rest retrospective observational analyses. Most publications dealt with hospitalized patients, only 18 publications in outpatients. Remdesivir, convalescent plasma, and synthetic anti-spike protein antibodies have been granted emergency use authorization in the United States. There is also support for glucocorticoid treatment of the COVID-19 respiratory distress syndrome. There is data supporting the use of several antiviral medications, some of which are in use in other countries.CONCLUSION Vaccines and antibodies are highly antigen specific. There is a need for antiviral agents in addition to mass immunization. It will be necessary for public health authorities to make hard decisions, with limited data, to prevent the continued spread of the disease and deaths.Competing Interest StatementDr. Binh Ngo is a speaker for Castle Biosciences. Dr. Armstrong reports grants and personal fees from Abbvie, grants and personal fees from Bristol-Myers Squibb, personal fees from Dermavant, grants from Dermira, grants and personal fees from Eli Lilly, grants and personal fees from Janssen, grants from Kyowa Hakko Kirin, grants and personal fees from LEO Pharma, grants and personal fees from Modernizing Medicine, grants and personal fees from Novartis, personal fees from Ortho-Dermatologics, personal fees from Pfizer, grants and personal fees from Regeneron, personal fees from Sanofi-Genzyme, personal fees from Science 37, Inc, grants from UCB Biopharma Dr. Dube reports grants from Gilead Sciences, outside the submitted work; Dr. Chaudhary has held stock in Gilead Sciences, Roche Holding and Moderna. Dr. Piccirillo reports personal fees from Daichii Sankyo, personal fees from GSK, personal fees from MSD, grants from Roche, grants and personal fees from AstraZeneca, non-financial support from Bayer, outside the submitted work;. Dr. Mussini is member of a Roche Data Safety Monitoring Board for tocilizumab Funding StatementNo external fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB needed for systematic analysisAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe have provided a comprehensive list of all clinical trials with their registration as Supplementary Table 1 and all completed trials as Supplementary Table 2 https://www.covid-trials.org/ https://clinicaltrials.gov/ https://www.who.int/ictrp/en/ https://reaganudall.org/covid-19